GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (HAM:HG6) » Definitions » Price-to-Owner-Earnings

Mayne Pharma Group (HAM:HG6) Price-to-Owner-Earnings : 3.62 (As of Jun. 24, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Mayne Pharma Group Price-to-Owner-Earnings?

As of today (2024-06-24), Mayne Pharma Group's share price is €2.82. Mayne Pharma Group's Owner Earnings per Share (TTM) ended in Jun. 2023 was €0.78. It's Price-to-Owner-Earnings for today is 3.62.


The historical rank and industry rank for Mayne Pharma Group's Price-to-Owner-Earnings or its related term are showing as below:

HAM:HG6' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.35   Med: 33.33   Max: 886.96
Current: 3.63

During the past 13 years, the highest Price-to-Owner-Earnings of Mayne Pharma Group was 886.96. The lowest was 2.35. And the median was 33.33.


HAM:HG6's Price-to-Owner-Earnings is ranked better than
96.49% of 427 companies
in the Drug Manufacturers industry
Industry Median: 24.5 vs HAM:HG6: 3.63

As of today (2024-06-24), Mayne Pharma Group's share price is €2.82. Mayne Pharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.85. Therefore, Mayne Pharma Group's PE Ratio for today is At Loss.

As of today (2024-06-24), Mayne Pharma Group's share price is €2.82. Mayne Pharma Group's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.66. Therefore, Mayne Pharma Group's PE Ratio without NRI for today is At Loss.

During the past 13 years, Mayne Pharma Group's highest PE Ratio without NRI was 688.24. The lowest was 0.00. And the median was 43.02.


Mayne Pharma Group Price-to-Owner-Earnings Historical Data

The historical data trend for Mayne Pharma Group's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Price-to-Owner-Earnings Chart

Mayne Pharma Group Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.48

Mayne Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 3.48 -

Competitive Comparison of Mayne Pharma Group's Price-to-Owner-Earnings

For the Drug Manufacturers - General subindustry, Mayne Pharma Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mayne Pharma Group's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mayne Pharma Group's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Mayne Pharma Group's Price-to-Owner-Earnings falls into.



Mayne Pharma Group Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Mayne Pharma Group's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.82/0.78
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mayne Pharma Group  (HAM:HG6) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Mayne Pharma Group Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Mayne Pharma Group (HAM:HG6) Business Description

Traded in Other Exchanges
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Branded Products (BPD) and Portfolio Products Division (PPD). The Portfolio Products Division distributes dermatology products (branded and generic) in the US on a portfolio basis, The Branded Products Division distributes branded women's health products in the US. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.

Mayne Pharma Group (HAM:HG6) Headlines

No Headlines